间充质干细胞治疗脊髓小脑性共济失调

背景：脊髓小脑性共济失调是临床上较常见的以进行性加重的四肢共济运动障碍为主要临床表现的中枢神经系统变性疾病，常规药物治疗效果欠佳。目的：观察自体骨髓间充质干细胞以及异体脐带间充质干细胞输注治疗脊髓小脑性共济失调的临床效果。方法：对接受间充质干细胞治疗的27例确诊脊髓小脑性共济失调患者进行综合统计分析，其中6例行自体骨髓间充质干细胞腰穿治疗，21例行异体脐带间充质干细胞腰穿结合静脉输注治疗，两组患者均采用世界神经病联合会国际合作共济失调量表（International Cooperative Ataxia Rating Scale，ICARS）对患者治疗前后神经功能进行评定。结果与结论：所有27例脊髓小脑共济失调患者行间充质干细胞治疗过程中以及治疗前后均未及明显不良反应。其中6例患者采用自体骨髓间充质干细胞治疗后效果均不明显，另外21例患者行异体脐带间充质干细胞输注治疗，治疗后3个月与治疗前比较，患者自觉症状均有一定程度改善，ICARS评分明显降低（P〈0．05）。说明脐带间充质干细胞治疗是安全的，可以一定程度地改善脊髓小脑性共济失调患者的临床症状，提高患者生活质量。

Mesenchymal stem cells for the treatment of spinocerebellar ataxia

METHODS： A total of 27 spinocerebellar ataxia patients treated with mesenchymal stem cells treatment were included for comprehensive statistical analysis, Among these patients, six patients received autologous bone marrow mesenchymal stem cells lumbar puncture treatment and 21 patients received allogeneic umbilical cord mesenchymal stem cells lumbar puncture treatment combined with intravenous infusion. The neurologic function of the patients in the two groups was evaluated with International Cooperative Ataxia Rating Scale before and after treatment. RESULTS AND CONCLUSION： There was no obvious adverse effect in the 27 spinocerebellar ataxia patients during, before or after mesenchymal stem cells treatment. The effect of autologous bone marrow mesenchymal stem cells in six patents was not significant; for the other 21 patients treated with allogeneic umbilical cord mesenchymal stem cells transfusion, the subjective symptoms of the patients were improved, and the International Cooperative Ataxia Rating Scale scores were decreased significantly at 3 months after treatment when compared with those before treatment （P 〈 0.05）. The results suggest that umbilical cord mesenchymal stem cells treatment is safe and able to ameliorate the clinical symptoms and improve life quality of